Stockscreener 앱 받기
1.90
8.57%
0.15
시간 외 거래:
1.87
-0.03
-1.58%
전일 마감가:
$1.75
열려 있는:
$1.78
하루 거래량:
390.13K
Relative Volume:
0.81
시가총액:
$120.38M
수익:
$13.86M
순이익/손실:
$-81.74M
주가수익비율:
-1.4575
EPS:
-1.3036
순현금흐름:
$-66.98M
1주 성능:
+13.77%
1개월 성능:
-16.67%
6개월 성능:
-43.62%
1년 성능:
+59.66%
1일 변동 폭
$1.78
$1.96
1주일 범위
$1.54
$1.96
52주 변동 폭
$0.97
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
명칭
Pyxis Oncology Inc
전화
(617) 221-9059
주소
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.90 | 110.24M | 13.86M | -81.74M | -66.98M | -1.3036 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 재개 | Stifel | Buy |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2024-11-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-08-08 | 개시 | Stifel | Buy |
| 2024-05-07 | 재개 | Jefferies | Buy |
| 2024-02-09 | 개시 | BTIG Research | Buy |
| 2024-01-23 | 개시 | Leerink Partners | Outperform |
| 2023-09-05 | 개시 | RBC Capital Mkts | Outperform |
| 2021-11-02 | 개시 | BofA Securities | Neutral |
| 2021-11-02 | 개시 | Credit Suisse | Outperform |
| 2021-11-02 | 개시 | Jefferies | Buy |
모두보기
Pyxis Oncology Inc 주식(PYXS)의 최신 뉴스
Pyxis Oncology elects directors and ratifies auditor at annual meeting - Investing.com
Pyxis Oncology elects directors and ratifies auditor at annual meeting By Investing.com - Investing.com UK
Pyxis Oncology Stockholders Approve Directors and Auditor Slate - TipRanks
Pyxis Oncology (PYXS) shareholders elect Class II directors and ratify Ernst & Young as 2026 auditor - Stock Titan
Pyxis Oncology Inc. (PYXS) Q1 2026 Earnings: Narrower Loss Beats Estimates as Stock Rises on Clinical Progress - newsline.com
PYXIS ONCOLOGY INC (PYXS) Stock Price & Overview - ChartMill
Analysts See Nearly 3X Upside in Pyxis Oncology (PYXS) - Insider Monkey
PYXS Q1 2026 Earnings: Narrower-Than-Expected Loss Supports Stock UptickEarnings Quality Analysis - newsline.com
Number of shareholders of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Pyxis Oncology, Inc. - MLQ.ai
Pyxis Oncology Stock Draws Attention Again After Jefferies as Traders Eye MICVO Results - Bez Kabli
PYXS: Mid-year data will clarify MICVO's efficacy, safety, and pivotal trial path in head and neck cancer - TradingView
HC Wainwright & Co. maintains Pyxis Oncology (PYXS) buy recommendation - MSN
PYXS: Mid-year data will highlight MICVO's efficacy and safety in head and neck cancer, supporting pivotal plans - TradingView
Pyxis Oncology Inc. (PYXS) Q1 2026 Earnings: Narrower-than-expected loss as clinical pipeline advancesProfit Guidance Range - newsline.com
Pyxis Oncology (PYXS) Holds Steady at $1.80 as Biotech Sector Watches Key LevelsDealer Gamma - newsline.com
PYXS News | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
Pyxis Oncology Edges Higher as Shares Test Key Resistance LevelsUnusual Put Volume - The Legal Advocate
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
PYXS Q1 2026 Earnings: Better-than-Expected Loss Highlights Progress in Oncology PipelinePeak Earnings Alert - newsline.com
Pyxis Oncology Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ReactionEarnings Surprise Report - The Legal Advocate
PYXS: MICVO demonstrates high efficacy and improved safety in head and neck cancer with dose capping - TradingView
Pyxis Oncology (PYXS) Rating Reiterated as Buy by HC Wainwright & Co. | PYXS Stock News - GuruFocus
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Raises Target Price to $6 - Moomoo
RBC Capital Keeps Their Buy Rating on Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology (PYXS) Gets a Buy from Guggenheim - The Globe and Mail
Wedbush Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $5 to $7 - Moomoo
Pyxis Oncology, Inc. Faces Substantial Doubt as a Going Concern and Requires Additional Capital – 2026 Q1 Financial Report Highlights Risks and Challenges 25 – Minichart - Minichart
Pyxis Oncology Faces Urgent Capital Needs and Potential Dilution Risks Amid Market Volatility - TipRanks
Pyxis Oncology Shares Slide on Steeper 1Q Loss - Moomoo
Pyxis Oncology Reports Q1 2026 Financial Results and Advances MICVO ADC Toward Key Clinical Milestones in Head and Neck Cancer - Minichart
Pyxis Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Pyxis Oncology stock (US70611B1026): Q1 2026 loss widens to $23.3M - AD HOC NEWS
Pyxis Oncology (PYXS) Q1 2026 loss deepens as MICVO trials expand and cash runway tightens - Stock Titan
Pyxis Oncology (PYXS) posts $23.3M Q1 loss and advances MICVO trials - Stock Titan
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones - marketscreener.com
BRIEF-Pyxis Oncology Q1 Net Income USD -23.272 Million - TradingView
Pyxis Oncology Reports First Quarter 2026 Financial Results - GlobeNewswire
Should You Sell Pyxis Oncology (PYXS) After -18.89% Drop? 2026-05-14Viral Trades - newser.com
Pyxis Oncology to Participate in Upcoming Investor Conferences - Caledonian Record
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - MSN
Pyxis Oncology stock (US70611B1026): Builds $540M cash pile after Q1 loss - AD HOC NEWS
Pyxis Oncology Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
TradingKey - TradingKey
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer - The Manila Times
SEC EDGAR Submission 0000950170-23-023950 - SEC.gov
Pyxis brings in former ImmunoGen dealmaker to advance MICVO - Stock Titan
Wedbush Initiates Pyxis Oncology at Outperform With $6 Price Target - marketscreener.com
Wedbush initiated coverage on Pyxis Oncology with a new price target - Quantisnow
Wedbush Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $6 - Moomoo
Pyxis Oncology Inc (PYXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):